From Liston Street Pulse:
Shares of Galectin Therapeutics Inc. (GALT), a biotechnology company, have surged in trading today after the Food and Drug Administration (FDA) granted a Fast Track Designation to the company's GR-MD-O2 for non-alcoholic steatohepatitis with hepatic fibrosis. GALT shares struck a 52-week high of $7.95 following the FDA news before paring some of their gains. At […]
The post Galectin Therapeutics Soars on FDA News appeared first on Liston Street Pulse.
Created by Stock Researching | Dec 13, 2016
Created by Stock Researching | Dec 04, 2016
Created by Stock Researching | Dec 02, 2016
Created by Stock Researching | Nov 19, 2016
Created by Stock Researching | Nov 10, 2016
Created by Stock Researching | Oct 05, 2015